Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia.
Hydroxyurea (HU) enhances fetal hemoglobin (Hb) production. An increase in total Hb level has been repeatedly reported during HU treatment in patients with sickle cell disease and in several patients with beta-thalassemia intermedia. Effects in patients with beta-thalassemia major are controversial. We now report a marked elevation of total Hb levels with HU that permitted regular transfusions to be stopped in 7 children with transfusion-dependent beta-thalassemia. The median follow-up was 19 +/- 3 months (range, 13-21 months). We conclude that HU can eliminate transfusional needs in children with beta-thalassemia major, which could be particularly useful in countries such as Algeria, where supplies of blood or chelating agents are limited.
Bradai
Mohamed
M
Service d'Hématologie, Hôpital Franz Fanon, Blida, Algeria.
Abad
Mohand Tayeb
MT
Pissard
Serge
S
Lamraoui
Fatima
F
Skopinski
Laurent
L
de Montalembert
Mariane
M
D000293:Adolescent; D001803:Blood Transfusion; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006454:Hemoglobins / Q000032:analysis / Q000096:biosynthesis / Q000187:drug effects; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D008297:Male; D016896:Treatment Outcome; D017086:beta-Thalassemia / Q000097:blood / Q000188:drug therapy* / Q000628:therapy
D006454:Hemoglobins; D006918:Hydroxyurea